4.0 Article

Health and Cardiometabolic Disease in Transgender Adults in the United States: Behavioral Risk Factor Surveillance System 2015

Journal

JOURNAL OF THE ENDOCRINE SOCIETY
Volume 2, Issue 4, Pages 349-360

Publisher

ENDOCRINE SOC
DOI: 10.1210/js.2017-00465

Keywords

gender nonconforming; health insurance; myocardial infarction; transgender

Ask authors/readers for more resources

Context: Little is known about the health of transgender adults in the United States, a growing population. There have been no large reports examining differences in health status and cardiometabolic disease in subgroups of transgender adults [female-to-male (FTM), male-to-female (MTF), and gender nonconforming (GNC)] in the United States. Objective: Compare the health status and prevalence of cardiometabolic disease among specific subgroups of transgender adults (FTM, MTF, GNC) with those of cisgender adults in the United States. Design: Secondary data analysis based on the 2015 Behavioral Risk Factor Surveillance System survey. Setting: The 22 states in the United States that asked about transgender identity. Participants: Noninstitutionalized adults age $ 18 years who reside in the United States, identified through telephone-based methods. Main Outcome Measures: Data were extracted for respondents who answered the transgender identity question. Weighted percentages are given for all measures. Adjusted odds ratios (ORs) are reported for health status and cardiometabolic disease measures. Results: FTM adults have a higher odds of being uninsured than both cisgender women [OR 3.8; 95% confidence interval (CI), 2.1 to 7.1] and cisgender men (OR 2.5; 95% CI, 1.4 to 4.7). MTF adults have a higher odds of reporting myocardial infarction than cisgender women (OR 2.9; 95% CI, 1.6 to 5.3) but not cisgender men. Conclusions: There are significant differences in health status measures and cardiometabolic health between subgroups of transgender adults and cisgender adults. There is a need for additional research to understand the societal and medical (e.g., hormone therapy) effects on these outcomes. Copyright (c) 2018 Endocrine Society

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available